Helikon Investments Ltd Acquires Stake in Grifols, S.A.

Helikon Investments Ltd has recently made a significant investment in Grifols, S.A. (NASDAQ:GRFS), purchasing a new stake during the fourth quarter of the year. According to their latest filing with the Securities and Exchange Commission (SEC), the fund acquired 78,010 shares of the biotechnology company, which is estimated to be worth around $580,000. This investment constitutes 0.1% of Helikon Investments Ltd's overall investment portfolio, making Grifols their 19th largest holding.

Other Investors in Grifols

In addition to Helikon Investments, several other hedge funds have either bought or sold shares of Grifols. Notably, Bank of Montreal Can has increased its stake in Grifols by 12.4% during the second quarter. They now own 70,640 shares valued at approximately $446,000 after purchasing an additional 7,786 shares in the last quarter. Furthermore, AQR Capital Management LLC entered a new position in Grifols worth $89,000 during the same period. B. Riley Wealth Advisors Inc. also made an investment in Grifols, with a stake worth $359,000. Additionally, Brandes Investment Partners LP has raised its holdings in Grifols by 8.7%, now owning 18,596,790 shares valued at $117,242,000 after acquiring an extra 1,481,924 shares. Lastly, Point72 Asset Management L.P. increased its position by 34.4%, now holding 596,845 shares valued at $3,763,000 following an additional acquisition of 152,700 shares.

Analyst Recommendations

In recent investment news, Berenberg Bank has upgraded Grifols to a "strong-buy" rating as of October 29th. This shows renewed confidence in the stock's potential performance.

Grifols Stock Performance

As of Monday, GRFS shares opened at $7.35, reflecting a decrease of 1.6%. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26, and a quick ratio of 0.79. The fifty-day moving average price for Grifols is $7.66, while the 200-day moving average stands at $8.19. Over the past year, the stock has experienced a low of $5.30 and a high of $9.96.

About Grifols

Grifols, S.A. operates as a plasma therapeutic company with a strong presence in Spain, the United States, Canada, and globally. The company specializes in various healthcare products, including immunoglobulin treatments for immunodeficiencies, albumin for restoring circulatory volume and protein loss associated with severe medical conditions, and several clotting factors for hemophilia treatment. Additionally, they offer treatments for genetic diseases and conditions like Alzheimer's disease through plasma exchange.

Considerations for Investors

For those evaluating Grifols as a potential investment, it's important to know that while the stock currently holds a "Moderate Buy" rating among analysts, there are other stocks that analysts believe could yield better returns.

Investment, Stocks, Biotechnology